Biotech Equity Investments at a Premium to Market, Part II
In Vivo breaks out equity investments at a premium to market in biotech deals from 1993 to 1995, comparing those in which the program licensed was in the R&D stage to those in which there was a product in Phase I or later.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.